Skip to content

The Safety and Efficacy of AOXMED Reparing Cosmetics Containing MLYATT-1002 for Repairing Acne Scar after Ablative Fractional Laser

The Safety and Efficacy of AOXMED Reparing Cosmetics Containing MLYATT-1002 for Repairing Acne Scar after Ablative Fractional Laser

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058017
Enrollment
Unknown
Registered
2022-03-26
Start date
2022-04-01
Completion date
Unknown
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Scar

Interventions

Experimental group:The experimental half face was treated with AOXMED intensive soothing repair serum, while the control half face was treated with blank matrix serum

Sponsors

The First Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Female subjects aged 18-50 years; 2. Receiving same-day dot matrix carbon dioxide laser; 3. The treatment area is on the face; 4. Agree to take photos before, after and during the return visit; 5. Voluntary informed consent.

Exclusion criteria

Exclusion criteria: 1. Suffering from a disease that severely affects the healing of wounds; 2. Patients who are allergic to the ingredients of the product or have allergic constitution; 3. Lactating or pregnant patients; 4. Use other products after laser surgery; 5. Have a history of heart, brain, lung, liver, kidney and other important organ diseases; 6. History of mental and mental illness; 7. Infection at the treatment site; 8. Patients with active herpes simplex.

Design outcomes

Primary

MeasureTime frame
transepidermal water loss (TEWL);erythema index;melanin index;

Secondary

MeasureTime frame
time for decrustation;clinical score;the subjects used a sensory assessment questionnaire;image analysis;

Countries

China

Contacts

Public ContactWang Yin

Meidasi (Shanghai) Biotech Co., Ltd.

awang@aoxmed.com+86 13916667201

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026